Genomma Lab Internacional, S.A.B. de C.V. (GNMLF)
| Market Cap | 808.85M -29.5% |
| Revenue (ttm) | 975.55M -9.5% |
| Net Income | 93.25M +21.3% |
| EPS | 0.10 +23.2% |
| Shares Out | n/a |
| PE Ratio | 8.67 |
| Forward PE | 6.33 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,000 |
| Open | 0.8350 |
| Previous Close | n/a |
| Day's Range | 0.8350 - 0.8350 |
| 52-Week Range | 0.8300 - 1.0800 |
| Beta | 0.14 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 22, 2026 |
About Genomma Lab Internacional
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Mexico and internationally. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products to prevent hair loss, ointment for muscle pain, anti-fungal treatments for the relief of colitis, products to counter stress levels, anti-wrinkles, anta... [Read more]
Financial Performance
In 2025, Genomma Lab Internacional's revenue was 17.54 billion, a decrease of -5.73% compared to the previous year's 18.61 billion. Earnings were 1.61 billion, an increase of 8.10%.
Financial numbers in MXN Financial StatementsNews
Genomma Lab Internacional Earnings Call Transcript: Q2 2026
Sequential improvement in Mexico and strong LATAM growth offset ongoing U.S. weakness and market contraction. Gross margin expanded on productivity, while EBITDA margin declined due to operational deleverage. Gradual recovery and margin improvement are expected in 2026.
Genomma Lab Internacional Earnings release: Q2 2026
Genomma Lab Internacional released its Q2 2026 earnings on July 23, 2026, summarizing the period's financial results.
Genomma Lab Internacional Announces Long-Term Debt Refinancing Transaction
MEXICO CITY, July 22, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies...
Genomma Lab initiated with a Hold at Jefferies
Jefferies initiated coverage of Genomma Lab (GNMLF) with a Hold rating and MXN 16 price target The firm cites the company’s recent operational challenges and limited visibility on near-term catalysts…
Genomma Lab Internacional S.A.B. de C.V. Second Quarter 2026 Earnings Results Conference Call
MEXICO CITY, July 6, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company") today announced that it will report its Second Quarter 2026 Earnings R...
GENOMMA LAB INTERNACIONAL ANNOUNCES SIXTEENTH DIVIDEND PAYMENT
MEXICO CITY, June 29, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies...
Genomma Lab Internacional Earnings Call Transcript: Q1 2026
Net sales declined 4.9% year-over-year due to FX headwinds and weak Mexican consumption, but gross margin expanded and LATAM delivered strong growth. Management expects margin pressure through Q3 as investments defend market share, with recovery in Mexico anticipated later in 2026.
Genomma Lab Internacional Earnings release: Q1 2026
Genomma Lab Internacional released its Q1 2026 earnings on April 23, 2026, summarizing the period's financial results.
Genomma Lab Internacional Announces Results for the First Quarter 2026
MEXICO CITY, April 22, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the first quarter 2026.
Genomma Lab Internacional S.A.B. de C.V. First Quarter 2026 Earnings Results Conference Call
MEXICO CITY, April 13, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company") today announced that it will report its First Quarter 2026 Earnings R...
Genomma Lab Internacional Slides: Corporate presentation
Genomma Lab Internacional has posted slides in relation to its latest quarterly earnings report, which was published on March 4, 2026.
Genomma Lab Internacional Earnings Call Transcript: Q4 2025
2025 saw a deliberate inventory normalization in Mexico, leading to lower sales but resilient margins and strong cash flow. Productivity gains and disciplined cost management support a positive 2026 outlook, with gradual top-line recovery and EBITDA margin guidance of 23%-23.5%.
Genomma Lab Internacional Earnings release: Q4 2025
Genomma Lab Internacional released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.
Genomma Lab Internacional Annual report: Q4 2025
Genomma Lab Internacional has published its Q4 2025 annual report on February 26, 2026.
Genomma Lab Internacional Announces Results for the Fourth Quarter and Full Year 2025
MEXICO CITY, Feb. 25, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the fourth quarter and full year 2025.
Genomma Lab Internacional S.A.B. de C.V. Fourth Quarter 2025 Earnings Results Conference Call
MEXICO CITY, Jan. 30, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company") today announced that it will report its Fourth Quarter 2025 Earnings R...
GENOMMA LAB INTERNACIONAL ANNOUNCES FOURTEENTH DIVIDEND PAYMENT
MEXICO CITY , Dec. 23, 2025 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companie...
Genomma Lab Internacional Earnings Call Transcript: Q3 2025
Sales declined due to FX and weak seasons, but EBITDA margin remained strong at 23.7% as cost efficiencies offset top-line pressure. Growth initiatives, innovation, and digital expansion are expected to drive recovery by 2026, with productivity savings reinvested to support this plan.
Genomma Lab Internacional Earnings release: Q3 2025
Genomma Lab Internacional released its Q3 2025 earnings on October 23, 2025, summarizing the period's financial results.
Genomma Lab Internacional Announces Results for the Third Quarter 2025
MEXICO CITY , Oct. 22, 2025 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the third quarter of 2025.
Genomma Lab Internacional S.A.B. de C.V. Third Quarter 2025 Earnings Results Conference Call
MEXICO CITY , Oct. 8, 2025 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company") today announced that it will report its Third Quarter 2025 Earnings Re...
Genomma Lab Internacional Earnings Call Transcript: Q2 2025
Q2 2025 saw modest sales growth, strong EBITDA margin expansion, and a 65% increase in free cash flow, despite currency headwinds and a weak beverage season in Mexico. Outlook for 2025 is cautious, but gradual growth is expected in 2026, supported by innovation, distribution expansion, and digital initiatives.
Genomma Lab Internacional Earnings release: Q2 2025
Genomma Lab Internacional released its Q2 2025 earnings on July 24, 2025, summarizing the period's financial results.
Genomma Lab Internacional Announces Results for the Second Quarter 2025
MEXICO CITY , July 23, 2025 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the second quarter of 2025.
GENOMMA LAB INTERNACIONAL ANNOUNCES TWELFTH DIVIDEND PAYMENT
MEXICO CITY , June 23, 2025 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companie...